Immunovant, Inc. (IMVT)

Market Cap	3.68B
Revenue (ttm)	n/a
Net Income (ttm)	-259.34M
Shares Out	146.05M
EPS (ttm)	-1.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	874,635
Open	25.28
Previous Close	25.43
Day's Range	24.94 - 25.85
52-Week Range	18.16 - 45.58
Beta	0.72
Analysts	Strong Buy
Price Target	47.93 (+90.43%)
Earnings Date	May 29, 2024

About IMVT

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Peter Salzmann M.B.A., M.D.
• Employees: 207
• Stock Exchange: NASDAQ
• Ticker Symbol: IMVT

Analyst Forecast

According to 16 analysts, the average rating for IMVT stock is "Strong Buy." The 12-month stock price forecast is $47.93, which is an increase of 90.43% from the latest price.

Price Target

$47.93

(90.43% upside)

Analyst Consensus: Strong Buy